Status:
COMPLETED
Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Invasive Breast Carcinoma
Eligibility:
FEMALE
18-75 years
Phase:
NA
Brief Summary
This clinical trial studies the feasibility of implementing various adaptive training exercise programs to improve cardiorespiratory fitness in patients after receiving breast cancer treatment. Inform...
Detailed Description
OUTLINE: Patients are randomized to the interventional groups or control group. INTERVENTION GROUPS: Patients are randomized to 1 of 2 interventional arms. ARM I: Patients participate in aerobic exe...
Eligibility Criteria
Inclusion
- Age 18 - 75 years, inclusive
- Female gender
- Prior diagnosis of invasive breast cancer
- Completion of chemotherapy or receipt of trastuzumab (Herceptin) therapy within the past 6 - 60 months (0.5 - 5 years)
- Reduced cardiorespiratory functional capacity, defined as below the median estimated CRF for age/sex-matched controls
Exclusion
- Actively receiving radiation treatment
- Medical history of heart failure, coronary artery disease or arrhythmia
- Contraindications to cardiopulmonary exercise testing (CPET)
- Contraindications to magnetic resonance imaging (MRI) (e.g ferromagnetic cerebral aneurysm clips or other intraorbital/intracranial metal; pacemakers, defibrillators, functioning neurostimulator devices, non-compatible MRI tissue expanders or breast implants, or other implanted non-compatible MRI devices), weight over 550 lbs, or symptomatic claustrophobia
- Contraindications to exercise, including a history of surgery with sequelae that restrict ability to exercise safely or comfortably
- Unwilling to complete intervention procedures or outcome measures
Key Trial Info
Start Date :
January 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2022
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04667481
Start Date
January 5 2022
End Date
November 10 2022
Last Update
February 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109